Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Corey

Showing results (81-90 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Clinical Microbiology|October 23, 2009
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trialIn-Gyu Bae, Giang T Tonthat, Martin E Stryjewski, et al.
BMC Infectious Diseases|June 3, 2014
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyMartin E Stryjewski, Arnold Lentnek, William O'Riordan, et al.
Critical Care Medicine|December 20, 2007
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremiaAnna Lisa Crowley, Gail E Peterson, Daniel K Benjamin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 17, 2005
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremiaVance G Fowler, Anita Justice, Catrin Moore, et al.
American Journal of Infection Control|May 22, 2012
Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen typeLuke F Chen, Jean Marie Arduino, Shubin Sheng, et al.
The New England Journal of Medicine|June 5, 2014
Single-dose oritavancin in the treatment of acute bacterial skin infectionsG Ralph Corey, Heidi Kabler, Purvi Mehra, et al.
The American Journal of Medicine|March 5, 2005
Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremiaFadi El-Ahdab, Daniel Kelly Benjamin, Andrew Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
Repeat infective endocarditis: differentiating relapse from reinfectionVivian H Chu, Daniel J Sexton, Christopher H Cabell, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Pageof 16

Showing results (81-90 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Journal of Clinical Microbiology|October 23, 2009
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trialIn-Gyu Bae, Giang T Tonthat, Martin E Stryjewski, et al.
BMC Infectious Diseases|June 3, 2014
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE studyMartin E Stryjewski, Arnold Lentnek, William O'Riordan, et al.
Critical Care Medicine|December 20, 2007
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremiaAnna Lisa Crowley, Gail E Peterson, Daniel K Benjamin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 17, 2005
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremiaVance G Fowler, Anita Justice, Catrin Moore, et al.
American Journal of Infection Control|May 22, 2012
Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen typeLuke F Chen, Jean Marie Arduino, Shubin Sheng, et al.
The New England Journal of Medicine|June 5, 2014
Single-dose oritavancin in the treatment of acute bacterial skin infectionsG Ralph Corey, Heidi Kabler, Purvi Mehra, et al.
The American Journal of Medicine|March 5, 2005
Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremiaFadi El-Ahdab, Daniel Kelly Benjamin, Andrew Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
Repeat infective endocarditis: differentiating relapse from reinfectionVivian H Chu, Daniel J Sexton, Christopher H Cabell, et al.
Journal of Medical Microbiology|March 21, 2020
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infectionsStephanie Noviello, G Ralph Corey, Thomas L Holland, et al.
Pageof 16